159 related articles for article (PubMed ID: 37689551)
21. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
22. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
[TBL] [Abstract][Full Text] [Related]
23. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
24. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
[TBL] [Abstract][Full Text] [Related]
25. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
26. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
Paoletti X; Oba K; Bang YJ; Bleiberg H; Boku N; Bouché O; Catalano P; Fuse N; Michiels S; Moehler M; Morita S; Ohashi Y; Ohtsu A; Roth A; Rougier P; Sakamoto J; Sargent D; Sasako M; Shitara K; Thuss-Patience P; Van Cutsem E; Burzykowski T; Buyse M;
J Natl Cancer Inst; 2013 Nov; 105(21):1667-70. PubMed ID: 24108811
[TBL] [Abstract][Full Text] [Related]
27. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
Front Oncol; 2022; 12():810580. PubMed ID: 35155246
[TBL] [Abstract][Full Text] [Related]
28. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
[TBL] [Abstract][Full Text] [Related]
29. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
30. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
[TBL] [Abstract][Full Text] [Related]
31. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
Colloca G; Venturino A
Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
[TBL] [Abstract][Full Text] [Related]
32. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma.
Nakashima K; Horita N; Nagai K; Manabe S; Murakami S; Ota E; Kaneko T
J Thorac Oncol; 2016 Sep; 11(9):1574-85. PubMed ID: 27178983
[TBL] [Abstract][Full Text] [Related]
33. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
34. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
Maeda H; Takeda K; Urushihara H; Kurokawa T
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1334. PubMed ID: 33455091
[TBL] [Abstract][Full Text] [Related]
35. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
[TBL] [Abstract][Full Text] [Related]
36. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
He Q; Li Q; Lv F; Kaitin KI; Shao L
Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
[TBL] [Abstract][Full Text] [Related]
37. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
38. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
Makris EA; MacBarb R; Harvey DJ; Poultsides GA
Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
[TBL] [Abstract][Full Text] [Related]
39. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
40. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
Dimopoulos M; Sonneveld P; Manier S; Lam A; Roccia T; Schecter JM; Cost P; Pacaud L; Poirier A; Tremblay G; Lan T; Valluri S; Kumar S
BMC Cancer; 2024 Apr; 24(1):541. PubMed ID: 38684948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]